Quantitative PSMA-PET parameters in localized prostate cancer: prognostic and potential predictive value

Research output: Contribution to journalResearch articleContributedpeer-review

Contributors

  • Stephanie Bela Andela - , Humboldt University of Berlin (Author)
  • Holger Amthauer - , Humboldt University of Berlin (Author)
  • Christian Furth - , Humboldt University of Berlin (Author)
  • Julian M. Rogasch - , Humboldt University of Berlin (Author)
  • Marcus Beck - , Humboldt University of Berlin (Author)
  • Felix Mehrhof - , Humboldt University of Berlin (Author)
  • Pirus Ghadjar - , Humboldt University of Berlin (Author)
  • Jörg van den Hoff - , Helmholtz-Zentrum Dresden-Rossendorf (Author)
  • Tobias Klatte - , Humboldt University of Berlin (Author)
  • Rana Tahbaz - , Humboldt University of Berlin (Author)
  • Daniel Zips - , Humboldt University of Berlin, Charité – Universitätsmedizin Berlin, German Cancer Research Center (DKFZ) (Author)
  • Frank Hofheinz - , Helmholtz-Zentrum Dresden-Rossendorf (Author)
  • Sebastian Zschaeck - , Humboldt University of Berlin (Author)

Abstract

Background: PSMA-PET is increasingly used for staging prostate cancer (PCA) patients. However, it is not clear if quantitative imaging parameters of positron emission tomography (PET) have an impact on disease progression and are thus important for the prognosis of localized PCA. Methods: This is a monocenter retrospective analysis of 86 consecutive patients with localized intermediate or high-risk PCA and PSMA-PET before treatment The quantitative PET parameters maximum standardized uptake value (SUVmax), tumor asphericity (ASP), PSMA tumor volume (PSMA-TV), and PSMA total lesion uptake (PSMA-TLU = PSMA-TV × SUVmean) were assessed for their prognostic significance in patients with radiotherapy or surgery. Cox regression analyses were performed for biochemical recurrence-free survival, overall survival (OS), local control, and loco-regional control (LRC). Results: 67% of patients had high-risk disease, 51 patients were treated with radiotherapy, and 35 with surgery. Analysis of metric PET parameters in the whole cohort revealed a significant association of PSMA-TV (p = 0.003), PSMA-TLU (p = 0.004), and ASP (p < 0.001) with OS. Upon binarization of PET parameters, several other parameters showed a significant association with clinical outcome. When analyzing high-risk patients according to the primary treatment approach, a previously published cut-off for SUVmax (8.6) showed a significant association with LRC in surgically treated (p = 0.048), but not in primary irradiated (p = 0.34) patients. In addition, PSMA-TLU (p = 0.016) seemed to be a very promising biomarker to stratify surgical patients. Conclusion: Our data confirm one previous publication on the prognostic impact of SUVmax in surgically treated patients with high-risk PCA. Our exploratory analysis indicates that PSMA-TLU might be even better suited. The missing association with primary irradiated patients needs prospective validation with a larger sample size to conclude a predictive potential. Trial registration Due to the retrospective nature of this research, no registration was carried out.

Details

Original languageEnglish
Article number97
JournalRadiation oncology
Volume19
Issue number1
Publication statusPublished - Dec 2024
Peer-reviewedYes
Externally publishedYes

External IDs

PubMed 39080696

Keywords

Sustainable Development Goals

Keywords

  • Positron emission tomography, Prognostic value, Prostate cancer, Prostate-specific membrane antigen, PSMA, Quantitative PET parameters